share_log

Intelligent Bio Solutions | D: Filing D

Intelligent Bio Solutions | D: Filing D

Intelligent Bio Solutions | D:發行公告
美股SEC公告 ·  03/22 22:02

牛牛AI助理已提取核心訊息

Intelligent Bio Solutions Inc. has successfully completed an exempt offering of securities, as indicated in a new Form D notice filed with the SEC. The offering, which closed on March 12, 2024, raised a total of $10,100,683 USD. The company, incorporated in Delaware and operating in the healthcare sector, specifically within the 'Other Health Care' category, has not disclosed its revenue range or aggregate net asset value. The securities offered included equity and options, warrants, or other rights to acquire another security. A minimum investment of $10,000 USD was accepted from outside investors, with a total of 8 investors participating in the offering. Sales commissions totaled $910,455 USD, paid to Ladenburg Thalmann & Co. Inc., which also received common stock warrants and reimbursement expenses. No proceeds from the offering are to be used for payments to executive officers, directors, or promoters. Intelligent Bio Solutions' principal place of business is located in New York, New York, with key executives including CEO Harry Simeonidis and CFO Spiro Sakiris.
Intelligent Bio Solutions Inc. has successfully completed an exempt offering of securities, as indicated in a new Form D notice filed with the SEC. The offering, which closed on March 12, 2024, raised a total of $10,100,683 USD. The company, incorporated in Delaware and operating in the healthcare sector, specifically within the 'Other Health Care' category, has not disclosed its revenue range or aggregate net asset value. The securities offered included equity and options, warrants, or other rights to acquire another security. A minimum investment of $10,000 USD was accepted from outside investors, with a total of 8 investors participating in the offering. Sales commissions totaled $910,455 USD, paid to Ladenburg Thalmann & Co. Inc., which also received common stock warrants and reimbursement expenses. No proceeds from the offering are to be used for payments to executive officers, directors, or promoters. Intelligent Bio Solutions' principal place of business is located in New York, New York, with key executives including CEO Harry Simeonidis and CFO Spiro Sakiris.
正如向美國證券交易委員會提交的新D表通知所示,Intelligent Bio Solutions Inc.已成功完成證券的豁免發行。此次發行於2024年3月12日結束,共籌集了10,100,683美元。該公司在特拉華州註冊成立,從事醫療保健行業,特別是 “其他醫療保健” 類別,尚未透露其收入範圍或總淨資產價值。提供的證券包括股票和期權、認股權證或其他收購其他證券的權利。接受了外部投資者的最低投資額爲10,000美元,共有8名投資者參與了此次發行。銷售佣金總額爲910,455美元,支付給拉登堡塔爾曼公司。Inc.,該公司還收到了普通股認股權證和報銷費用。本次發行的收益不得用於向執行官、董事或發起人付款。Intelligent Bio Solutions的主要營業地點位於紐約州紐約,其主要高管包括首席執行官哈里·西蒙尼迪斯和首席財務官斯皮羅·薩基里斯。
正如向美國證券交易委員會提交的新D表通知所示,Intelligent Bio Solutions Inc.已成功完成證券的豁免發行。此次發行於2024年3月12日結束,共籌集了10,100,683美元。該公司在特拉華州註冊成立,從事醫療保健行業,特別是 “其他醫療保健” 類別,尚未透露其收入範圍或總淨資產價值。提供的證券包括股票和期權、認股權證或其他收購其他證券的權利。接受了外部投資者的最低投資額爲10,000美元,共有8名投資者參與了此次發行。銷售佣金總額爲910,455美元,支付給拉登堡塔爾曼公司。Inc.,該公司還收到了普通股認股權證和報銷費用。本次發行的收益不得用於向執行官、董事或發起人付款。Intelligent Bio Solutions的主要營業地點位於紐約州紐約,其主要高管包括首席執行官哈里·西蒙尼迪斯和首席財務官斯皮羅·薩基里斯。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生,只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。